- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The study by Nahata et al. (N=9, age 10 months – 10 years) shows that the elimination half-life of cefazolin in children averages 1.68 ± 0.55 hours. The total clearance and the apparent volume of distribution are 1.43 ± 0.54 ml/min/kg and 0.08 ± 0.03 l/kg respectively.
The study by Deguchi et al. shows that the percentage of the free fraction of cefazolin varies widely in neonates. The volume of distribution in neonates is 0.21–0.37 l/kg.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Infections by very sensitive Gram-positive microorganisms |
|---|
|
| Infections by less sensitive Gram-positive microorganisms and Gram-negative pathogens |
|---|
| Perioperative prophylaxis |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Dose adjustments <14 years
Cl 40 - 70 mL/min: Start with normal single dose, continue at 60 % of daily dose with divided in 2 doses with dosing interval of 12 hours
Cl 20 - 40 mL/min: Start with normal single dose, continue at 25 % of daily dose with divided in 2 doses with dosing interval of 12 hours
Cl < 20 mL/min: Start with normal single dose, continue at 10 % of daily dose, with dosing interval of 24hours
Dose adjustments ≥ 14 years
Cl 35 - 54 mL/min: Normal daily dose (no dose adjustment), dosing interval at 8 hours
Cl 10 - 34 mL/min: Start with normal single dose, continue at 50% of normal daily dose, dosing interval at 12 hours
Cl < 10 mL/min: Start with normal single dose, continue at 50% of normal daily dose, dosing interval at 18-24 hours
[SmPC Cefazolin Fresenius]
Clinical consequences
Nephrotoxic symptoms (renal function disorder, tubular necrosis, interstitial nephritis) occur primarily at high dosages, in pre-existing renal function disorders and in concomitant treatment with other nephrotoxic substances. Convulsions can occur at very high doses. The time above the MIC determines the effect.
Patients on dialysis
No data known
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Thrombophlebitis, fever, nausea, vomiting, diarrhoea, obstipation, abnormal blood counts, temporarily elevated liver enzymes.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Cephalosporins can in general be given to patients who are hypersensitive to penicillin, although cross-reactions have been reported. Special care is indicated in patients who previously had anaphylactic responses to penicillins. Pseudomembranous colitis may occur during antibiotic use. If pseudomembranous colitis develops, the cefazolin treatment should be discontinued and an appropriate therapy started. In long-term use, checks of the blood counts and hepatic and renal function are desirable.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| First-generation cephalosporins | ||
|---|---|---|
| J01DB01 | ||
| Second-generation cephalosporins | ||
|---|---|---|
| J01DC02 | ||
| Third-generation cephalosporins | ||
|---|---|---|
| J01DD08 | ||
| J01DD01 | ||
| J01DD52 | ||
| J01DD02 | ||
| J01DD04 | ||
| Carbapenems | ||
|---|---|---|
| J01DH02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
- Deguchi Y, et al, Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts, J Pharm Sci, 1988, 77, 674-8
- Haessler D, et al, Antibiotic prophylaxis with cefazolin and gentamicin in cardiac surgery for children less than ten kilograms, J Cardiothorac Vasc Anesth, 2003, 17, 221-5
- Maher KO, et al, A retrospective review of three antibiotic prophylaxis regimens for pediatric cardiac surgical patients, Ann Thorac Surg, 2002, 74, 1195-200
- Nahata MC, et al, Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery, Eur J Drug Metab Pharmacokinet., 1991, 16, 49-52
- Eurocept International B.V., SPC Kefzol (RVG 06836) 30-01-2019, www.geneesmiddelinformatiebank.nl
- Bratzler DW et al. , Clinical practice guidelines for antimicrobial prophylaxis in surgery. , Surg Infect (Larchmt). , 2013 , Feb;14(1), 73-156
- Lorrot M et al. , Antibiotic therapy of bone and joint infections in children: proposals of the French Pediatric Infectious Disease Group. , Arch Pediatr. , 2017, 24(12S):S36-S41, DOI: 10.1016/S0929-693X(17)30517-1
- DeRonde KJ et al. , Management of Pediatric Acute Hematogenous Osteomyelitis, Part I: Antimicrobial Stewardship Approach and Review of Therapies for Methicillin-Susceptible Staphylococcus aureus, Streptococcus pyogenes, and Kingella kingae, Pharmacotherapy, 2018, 38(9):947-966, doi:10.1002/phar.2160
- Woods CR, Bradley JS, Chatterjee A, et al. , Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. , J Pediatric Infect Dis Soc., 2021, 10(8):801-844., DOI: 10.1093/jpids/piab027
- Pio, L., et al., Antibiotic prophylaxis in children undergoing abdominal surgery for neoplastic diseases., Infez Med, 2018, 26 (2), 122-125
- Salvador E, et al. , Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. , Clin Microbiol Infect., 2021, Mar;27(3), 413-419
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
